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Background: Esophageal cancer is the malignant tumor with very poor prognosis and increasing incidence often
diagnosed at very late stage, so the prognosis of affected patients is unsatisfactory, despite the development of
therapeutic option such as surgery, chemotherapy and radiotherapy. Consequently, there is a great need for
biomarkers to allow a tailored multimodality approach with increased efficiency. Altered expression of microRNAs
has been reported in wide range of malignancies, including esophageal cancer. The aim of this study was to
examine the expression levels of candidate microRNAs in esophageal cancer and evaluate their diagnostic and
prognostic potential.
Findings: Using quantitative real-time PCR, expression levels of 9 candidate microRNAs were examined in 62 tissue
samples, 23 esophageal adenocarcinomas, 22 esophageal squamous cell carcinomas and 17 adjacent esophageal
mucosa samples. MicroRNA expression levels were further analyzed in regards to clinico-pathological features of
esophageal cancer patients. We observed significantly decreased levels of miR-203 and increased levels of miR-21
in adenocarcinoma tissues when compared to normal mucosa. MiR-29c and miR-148 indicated good ability to
distinguish between histological subtypes of esophageal cancer. MiR-203 and miR-148 were linked to disease-free
survival and overall survival in esophageal adenocarcinoma patients, and miR-148 also in esophageal squamous
cell carcinoma patients.
Conclusions: Our data suggest that altered expression of miR-21, miR-29c, miR-148 and miR-203 are related to
neoplastic transformation and progression of the disease and these microRNAs could serve as a potential diagnostic
and prognostic biomarkers in esophageal cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4646922201567057Findings
Background
Esophageal cancer (EC) is the seventh most common
cancer worldwide and the sixth most common cause of
cancer death [1]. There are two main types of esophageal
cancer – adenocarcinoma and squamous cell carcinoma
with distinct etiology and epidemiology.* Correspondence: on.slaby@gmail.com
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unless otherwise stated.Esophageal adenocarcinoma (EAC) is one of the fastest
rising cancers in Western society. Incidence has increased
by 600% within the last 30 years [2]. The reason of
increasing incidence is not entirely clear but the main risk
factors are male sex (5 more often than female sex),
Caucasian race, chronic reflux disease and visceral obesity
[2]. In contrast, esophageal squamous cell carcinoma
(ESCC) is more prevalent in the developing world with
very high incidence areas found in East Asia mainly in
China [3]. While the main risk factors are smoking and
alcohol consumption, high diets in N-nitroso compounds,
fungal toxins, low in selenium, zinc, vitamins A and C and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Characteristic Prague cohort Olomouc cohort
Total 22 23
Gender Male 20 18
Female 2 5
Age 59 (49–70) 58 (34–79)
Histology Adenocarcinoma 17 6
Squamous cell carcinoma 5 17
Pre-operative chemotherapy Adenocarcinoma CDDP+FU 2x 0 6
ECF/ECX 17 0
Squamous Cell carcinoma CDDP+FU 2x 3 17
ECF/ECX 2 0
Tumor location Upper esophagus 0 0
Middle esophagus 20 11
Lower esophagus 2 12
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factors.
Both EAC and ESCC are usually detected at an advanced
stage, requiring a multimodal concept of therapy, however
the overall survival of esophageal cancer remains lowerFigure 1 Normalized expression levels of miR-203 and miR-21 in esophage
in esophageal adenocarcinoma compared to paired adjacent mucosa (P < 0.0
to paired adjacent mucosa (P = 0.0004). C) MiR-148a is up-regulated in esoph
carcinoma (P = 0.0014). D) MiR-29c is up-regulated in esophageal adeno
(P = 0.0446). EAC – esophageal adenocarcinoma; ESCC – esophagus squamouthan other solid tumors [4]. Although the treatments have
made great progress, the prognosis for patients with
advanced disease still remains poor and unsatisfactory [5].
Potentially curative treatments are followed by high rates of
disease recurrence. All these facts together clearly indicateal adenocarcinoma tissue and control mucosa. A) MiR-203 is decreased
001). B) MiR-21 is increased in esophageal adenocarcinoma compared
ageal adenocarcinoma compared to esophageal squamous cell
carcinoma compared to esophageal squamous cell carcinoma
s cell carcinoma; *P < 0.05; **P < 0.001; ***P < 0.0001
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enabling earlier detection and prognostic stratification.
MicroRNA (miRNA) are short non-coding RNA with
ability to regulate important cellular processes as differenti-
ation, cell cycle, proliferation or apoptosis. They are known
to be deregulated in most tumor types [6], in which they
can act as tumor suppressors or oncogenes. Altered miRNA
expression profiles are intensively studied also in esophageal
cancer. In this study, we hypothesized that selected miRNAs
can be identified as diagnostic and/or prognostic biomarkers
in EC. Thus, we analyzed 9 candidate miRNAs in EAC,
ESCC and non-tumor esophageal mucosa and investigated
their potential for diagnostic and prognostic usage in EC.
Methods
Study population
A total of 62 tissue samples from two esophageal cancer
cohorts were included in the study. First cohort (Motol
University Hospital, 3rd Department of Surgery, Prague,
Czech Republic) consisted of 17 EAC and 5 ESCC cases,
whereas for 17 EAC cases paired esophageal mucosa
samples were available. Second cohort (Palacky University,
Medical Faculty, Olomouc, Czech Republic) consisted of 6
EAC and 17 ESCC cases. All subjects were of the same
ethnicity (Caucasian). Clinico-pathological features includ-
ing age, sex, histology and treatment were recorded and
summarized in Table 1. Written informed consent wasTable 2 MiRNA expression levels in adenocarcinoma and pair





















MiRNAs with significant differences are bolded.obtained from the patients before starting this study. The
study has been approved by the local ethical committees
(Prague, Olomouc).
Tissue sample preparation and miRNA isolation
Forty-five samples of tumor tissue and seventeen samples of
non-cancerous esophageal mucosa were collected and stored
in RNAlater (Ambion, USA). Afterward, tissue samples were
homogenized (MagnaLyser, Roche), and total RNA enriched
for small RNA fraction was isolated using fenol-chloroform
extraction with TRIzol reagent (Ambion, USA). Concentra-
tion and purity of RNA were determined using a Nanodrop
ND-1000 (Thermo Scientific, USA), and RNA integrity was
measured by Agilent 2100 Bioanalyzer using Agilent RNA
6000 Nano Kit (Agilent Technologies, USA). Samples were
either stored at -80°C or further processed.
Quantitative real-time PCR
cDNA was synthesized from total RNA using miRNA-
specific primers according to the Taq-Man MicroRNA
Assay protocol (Applied Biosystems, USA). Real-time
polymerase chain reaction (PCR) was performed according
to manufacturing protocol (MicroRNA Assay, Applied
Biosystems, USA) using the Applied Biosystems 7500
Instrument as described previously [7]. All reactions
were run in triplicate, and average threshold cycle
and SD values were calculated.ed non-tumoral esophageal mucosa
cosa (n = 17) FC p-value
dian
%–75% percentile)
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The threshold cycle data were calculated by SDS 2.0.1
software (Applied Biosystems, USA). The average expres-
sion levels of measured miRNAs were normalized using
RNU44 as reference gene and subsequently analyzed by the
2-ΔCt method. Differences between expression levels in
paired samples were evaluated by non-parametric Wilcoxon
test. Differences between miRNA levels in EAC and ESCC
samples were evaluated by non-parametric Mann–Whitney
U-test. Survival analyses were carried out using the
log-rank test and Kaplan-Meier survival analysis. All
calculations were performed using Prism version 6.00
(GraphPad Software, San Diego, CA, USA). P-values of
less than 0.05 were considered statistically significant.
Results
miR-203 and miR-21 are able to distinguish EAC and
normal tissue
To determine whether the selected miRNAs (miR-200c,
miR-25, miR-27a, miR-7a, miR-29c, miR-203, miR-148a,
miR-21 a miR-31) have a diagnostic potential, expression
levels were analyzed for each miRNA in 17 EAC samples
and 17 paired adjacent mucosa. There were 2 miRNAs
differentially expressed in tumor tissue and adjacent
mucosa. MiR-203 levels were significantly down-regulated
in tumor tissue (fold change 0,19; p < 0,0001), miR-21
levels were significantly up-regulated in tumor tissueTable 3 Comparison of miRNAs expression levels in ESCC and





















MiRNAs with significant differences are bolded.(fold change 40,38; p = 0,0004) (Figure 1 A,B). No signifi-
cant difference was observed in the other examined miRNA
as summarized in Table 2.
miR-148 and miR-29c have ability to distinguish EAC and
ESCC tissues
To determine whether different expression levels of
analyzed miRNAs exist in EAC and ESCC tissues, we
performed qPCR analysis of selected miRNAs (miR-200c,
miR-25, miR-27a, miR-7a, miR-29c, miR-203, miR-148a,
miR-21 a miR-31) in 22 ESCC samples and 22 EAC sam-
ples. We found that miR-148 and miR-29c were de-
creased in ESCC when compared to EAC and have
ability to significantly distinguish ESCC and EAC
tissues (fold change 0,32; p = 0,0014; fold change 0,62;
p = 0,0446), respectively (Figure 1C,D). No significant
difference was observed in the other examined miRNA
as summarized in Table 3.
MiR-148 and miR-203 are associated with prognosis in EC
patients
EAC patients with decreased miR-203 levels showed
significantly shorter disease free survival (p = 0,026).
Down-regulation of miR-148 was associated with signifi-
cantly shorter overall survival (p = 0,0014) in ESCC
patients. Interestingly, opposite observation was reached
in EAC patients, where cases with up-regulation ofEAC tissues
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(p = 0,0145) and overall survival (p = 0,0016), indicating
opposite functioning of miR-148 in EAC and ESCC
(Figure 2A-D). There was no association with survival
observed in other examined miRNAs.
Discussion
Our results indicate that miR-203 plays role of tumor
suppressor in EAC since the expression levels of this
miRNA were significantly decreased in tumor tissue of
EAC patients. Those results are in compliance with another
studies, where miR-203 displayed stepwise decrease in
expression during malignant progression from healthy
tissue through Barrett’s esophagus to EAC [8-11].
Moreover, survival analysis showed significantly shorter
disease free survival of the EAC patients with low expres-
sion of miR-203 in our study. Another miRNA observed
to have different expression in EAC tissue and adjacent
mucosa is miR-21, which is well known as oncogene. In
our study, expression levels of miR-21 were significantly
higher in EAC tissue, which is in concordance with the
several previous studies [8,10-12]. We have not found
association of miR-21 and survival in our study, which is
contradictory to meta-analysis performed by Fu et al.,Figure 2 Survival analysis of miR-203 and miR-148 tissue levels in esophagea
A) Esophageal adenocarcinoma patients with low level of miR-203 have shor
patients with high level of miR-148 have shorter disease free survival (P = 0.01
have shorter overall survival (P = 0.0016). D) Esophageal squamous cell carcino
(P = 0.0014). DFS – disease free survival; OS – overall survival.where up-regulation of miR-21 could predict unfavorable
prognosis in esophageal cancer [12].
The second aim of our study was to discriminate EAC
from ESCC tissue. For the first time, we found that the
expression levels of miR-148a and miR-29c are significantly
higher in EAC when compared to ESCC tissue. Moreover
up-regulation of miR-148 could predict unfavorable prog-
nosis in EAC cancer and surprisingly favorable prognosis
in ESCC patients. It seems that miR-148 can play the role
of tumor suppressor or tumor oncogene depending on
histological subtype of esophageal cancer.
MiR-148 was not yet studied in association with esopha-
geal cancer, but it is known to act as oncogene and also as
tumor suppressor in different tumor types. Thus, Kim
et al. has reported the definition of miR-148a as a novel
prognostic oncomiR in glioblastoma with high levels con-
sidered as a risk factor for glioblastoma patients survival
[13]. When analyzed in vitro, miR-148a overexpression in-
creased cell growth, survival, migration, and invasion
in glioblastoma cells [13]. On the other hand, in gastric
cancer (GC), miR-148 acts as tumor suppressor and its
down-regulation is linked to the poor prognosis. MiR-
148a levels were found to be decreased in GC cell lines
and in GC tissue samples when compared to the adjacentl squamous cell carcinoma and esophageal adenocarcinoma patients.
ter disease free survival (P = 0.026). B) Esophageal adenocarcinoma
45). C) Esophageal adenocarcinoma patients with high level of miR-148
ma patients with low level of miR-148 have shorter overall survival
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GC [14-18]. Low expression of miR-148a was significantly
correlated with an advanced clinical stages, lymph node
metastasis, and poor clinical outcome [14].
Our data indicate, that miR-203 and miR-21 could
serve as diagnostic biomarkers. Further, miR-29c and
miR-148 have ability to distinguish between EAC and
ESCC histological subtypes of esophageal cancer. In future,
the diagnosis could be assessed for instance from non-
invasive brush biopsy of esophagus [19]. Moreover miR-
203 and miR-148 could serve as prognostic biomarker in
EAC, and miR-148 also in ESCC patients. Further studies
are needed to evaluate mechanistically dual functioning of
miR-148 in EAC and ESCC carcinogenesis.
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